Mounjaro 5mg Injection – Tirzepatide 5mg

$250

2 products sold in last 6 hours

Selling fast! Over 5 people have in their cart

Mounjaro 5mg Injection contains tirzepatide 5mg, a once-weekly injectable medicine that activates both GIP and GLP-1 receptors. It is used under medical supervision to improve blood glucose control in adults with type 2 diabetes and can also reduce appetite and food intake, potentially supporting weight reduction.

29 people are viewing this right now

Estimated Delivery : Up to 4 business days
Free Shipping & Returns : On all orders over $200

Guaranteed Safe And Secure Checkout

Description
Reviews(0)

Mounjaro 5mg Injection contains tirzepatide, a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist. It is administered once weekly by subcutaneous injection.

Tirzepatide works through two incretin pathways to enhance glucose-dependent insulin secretion, reduce glucagon secretion, slow gastric emptying, and influence appetite and food intake. These actions can improve blood glucose control and may contribute to weight reduction.

The 5mg dose is generally reached after an initial 2.5mg treatment period, provided the medicine is tolerated. Dose escalation should be performed according to the prescribing healthcare professional’s instructions.

Prescription Required.

Product Information




Product Information	Details
Brand Name	Mounjaro
Active Ingredient	Tirzepatide
Strength	5mg
Dosage Form	Injection
Drug Class	GIP/GLP-1 Receptor Agonist
Route	Subcutaneous
Frequency	Once weekly
Primary Use	Type 2 Diabetes Management
Prescription	Required

How It Works

Tirzepatide activates GIP and GLP-1 receptors, helping increase glucose-dependent insulin secretion, reduce glucagon secretion, slow gastric emptying, and regulate appetite and food intake.

Administration

Mounjaro 5mg is administered once weekly by subcutaneous injection, generally into the abdomen, thigh, or upper arm. It may be administered with or without food.

Rotate injection sites and follow the prescribed dosing schedule. Do not increase the dose without medical supervision.

Common Side Effects

Important Safety Information

Important risks include pancreatitis, gallbladder disease, dehydration and kidney problems, hypoglycemia when used with insulin or insulin secretagogues, and serious hypersensitivity reactions.

Mounjaro should not be used in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Inform your healthcare professional about all medicines you take, particularly insulin or sulfonylureas.

Storage

Store according to the manufacturer’s instructions. Keep refrigerated and protect from light. Do not freeze. Follow the product packaging and prescribing information for exact storage requirements.